Nanjing Medlander Medical Technology Co. Ltd. A (688273) — Cash Flow Reinvestment Rate

Latest as of December 2024: 3.85x

Nanjing Medlander Medical Technology Co. Ltd. A (688273) has a Cash Flow Reinvestment Rate of 3.85x as of December 2024, reinvesting CN¥471.54 Million (capex CN¥129.71 Million plus investments CN¥-341.83 Million) from operating cash flow of CN¥122.51 Million. See 688273 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

3.85x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥471.54 Million
Capex + Investments

Operating Cash Flow

CN¥122.51 Million
CNY

Capital Expenditures

CN¥129.71 Million
CNY

Nanjing Medlander Medical Technology Co. Ltd. A Cash Flow Reinvestment Rate (2020–2024)

Historical reinvestment intensity for Nanjing Medlander Medical Technology Co. Ltd. A across 5 annual periods. For the full cash flow conversion analysis, see Nanjing Medlander Medical Technology Co. operating cash flow efficiency.

Annual Cash Flow Reinvestment Rate for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)

Year-by-year capital reinvestment analysis for Nanjing Medlander Medical Technology Co. Ltd. A. See 688273 financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 3.85x CN¥471.54 Million CN¥122.51 Million CN¥129.71 Million ▲ +131.6%
2023 1.66x CN¥227.50 Million CN¥136.91 Million CN¥75.15 Million ▲ +49.7%
2022 1.11x CN¥140.57 Million CN¥126.67 Million CN¥54.26 Million ▲ +607.4%
2021 0.16x CN¥23.31 Million CN¥148.60 Million CN¥14.58 Million ▼ -59.2%
2020 0.38x CN¥50.41 Million CN¥131.10 Million CN¥25.91 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow